| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $2.1M | — |
| Cost of Revenue | $18.8M | — |
| R&D Expense | $25.0M | — |
| SG&A Expense | $66.7M | — |
| Operating Income | -$464.7M | — |
| Pre-tax Income | -$488.8M | — |
| Income Tax | -$13.5M | — |
| Net Income | -$293.3M | — |
| EPS (Basic) | -$5.39 | — |
| EPS (Diluted) | -$5.39 | — |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $60.4M | +443.7% |
| Accounts Receivable | $1.1M | +286.6% |
| Inventory | $1.6M | -69.0% |
| Current Assets | $83.2M | +242.4% |
| Total Assets | $599.2M | -33.8% |
| Current Liabilities | $76.3M | +10.0% |
| Long-term Debt | $8.3M | -39.0% |
| Total Liabilities |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$80.7M | — |
| Capital Expenditures | $1.4M | — |
| Investing Cash Flow | -$4.1M | — |
| Financing Cash Flow | $139.1M | — |
| Free Cash Flow | -$82.1M | — |
| $115.5M |
| -16.9% |
| Stockholders' Equity | $204.2M | -52.0% |